Blocking Extracellular Galectin-3 in Patients With Osteoarthritis
Status: | Recruiting |
---|---|
Conditions: | Arthritis, Osteoarthritis (OA) |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 40 - 80 |
Updated: | 4/17/2018 |
Start Date: | July 2016 |
End Date: | June 2018 |
Contact: | Yousif Hanna |
Phone: | 6177267938 |
The proposed study is a pilot, double-blind, randomized clinical trial comparing galectin-3
inhibition with MCP to placebo for the treatment of knee osteoarthritis.
inhibition with MCP to placebo for the treatment of knee osteoarthritis.
Inclusion Criteria:
1. Knee pain in at least one knee for more than half the days in the month prior to
screening
2. X-rays showing evidence of knee osteoarthritis by Kellgren and Lawrence Score two or
three, with definite osteophytes and possible or definite joint space narrowing,
consistent with mild to moderate knee osteoarthritis. If both knees are affected,
patients would choose the more severe knee for outcomes assessments.
3. Willingness to maintain stable analgesic regimen throughout the study period
Exclusion Criteria:
1. Diagnosis of fibromyalgia
2. Presence of an underlying inflammatory disease in the affected knee, including
Rheumatoid Arthritis, Psoriatic Arthritis, Gout, Pseudogout, or other inflammatory
disease.
3. Patients who cannot give consent will be excluded, as will patients who cannot speak,
read and understand English, as we will not have translated documents, consent forms,
and surveys for them.
4. While this supplement is considered very safe and low risk, patients with underlying
significant cytopenia (white blood cell count less than 4.0, hemoglobin less than 10,
or platelets less than 100), or with impaired renal function (glomerular filtration
rate less than 60) or elevated liver enzymes will be excluded as well.
We found this trial at
1
site
Click here to add this to my saved trials